Skip to search formSkip to main contentSkip to account menu

KW 2449

Known as: FLT3/ABL/Aurora Kinase Inhibitor KW-2449, KW-2449, KW2449 
An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IndazolesPiperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A.
2018
2018
An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW‐2449 in primates: irreversible inhibition of aldehyde oxidase and covalent…
We previously reported that KW‐2449, (E)‐1‐{4‐[2‐(1H‐Indazol‐3‐yl)vinyl]benzoyl}piperazine, a novel multikinase inhibitor… 
Review
2015
Review
2015
Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Aurora kinase A, B and C, are key regulators of mitosis and are over expressed in many of the human cancers, making them an ideal… 
2015
2015
Molecular characterization of the Parkinson's associated protein DJ-1
Mutations in DJ-1 (PARK7), a conserved protein of 189 amino acids, cause autosomal recessive cases of Parkinson’s disease (PD… 
2013
2013
FLT 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
634. 42. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and… 
Review
2010
Review
2010
FLT3 inhibitors for the treatment of acute myeloid leukemia.
The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and… 
2009
2009
Increased Plasma FLT3 Ligand Levels Following Chemotherapy May Interfere with the Clinical Efficacy of FLT3 Inhibitors.
Abstract 937 FLT3 mutations are relatively common in AML and are associated with a poor prognosis. A large number of different… 
2008
2008
KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.
Background: KW-2449 is a multi-kinase inhibitor against FLT3, ABL and ABL/T315I and Aurora kinases with IC50 values of 0.007, 0… 
2007
2007
KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .
Constitutive activation of FLT3 kinase is associated with poor prognosis in AML and is present in 30–40% of AML patients. KW-2449… 
2007
2007
A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and…
Background: Activating mutations of FMS-like tyrosine kinase 3 (FLT3) occur in 30% of patients (pts) with de novo AML and confer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)